Canaccord raised the firm’s price target on Castle Biosciences (CSTL) to $50 from $37 and keeps a Buy rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes momentum in the sector which began in the second half of this year, can be maintained in 2026. Among their covered companies, they maintain the highest level of conviction in the risk-reward profile and share price appreciation potential for Castle Biosciences.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle Biosciences reports inducement grants under Nasdaq listing rule
- Castle Biosciences announces new data on DecisionDx-UM, PRAME
- Castle Biosciences price target raised to $50 from $38 at BTIG
- Castle Biosciences announces publication of new SRMA on TissueCypher
- Castle announces publication of consensus paper on DecisionDx-Melanoma test